nodes	percent_of_prediction	percent_of_DWPC	metapath
Alosetron—CYP3A4—Thiotepa—urinary bladder cancer	0.109	0.221	CbGbCtD
Alosetron—CYP2E1—Etoposide—urinary bladder cancer	0.0978	0.198	CbGbCtD
Alosetron—CYP1A2—Fluorouracil—urinary bladder cancer	0.0678	0.137	CbGbCtD
Alosetron—CYP2C9—Fluorouracil—urinary bladder cancer	0.0611	0.124	CbGbCtD
Alosetron—CYP1A2—Etoposide—urinary bladder cancer	0.0566	0.114	CbGbCtD
Alosetron—CYP2C9—Cisplatin—urinary bladder cancer	0.0519	0.105	CbGbCtD
Alosetron—CYP3A4—Etoposide—urinary bladder cancer	0.0296	0.06	CbGbCtD
Alosetron—CYP3A4—Doxorubicin—urinary bladder cancer	0.0202	0.0409	CbGbCtD
Alosetron—CYP1A2—urine—urinary bladder cancer	0.0033	0.181	CbGeAlD
Alosetron—CYP2C9—urine—urinary bladder cancer	0.00313	0.172	CbGeAlD
Alosetron—CYP2E1—urine—urinary bladder cancer	0.00297	0.163	CbGeAlD
Alosetron—CYP3A4—urine—urinary bladder cancer	0.00239	0.131	CbGeAlD
Alosetron—CYP2E1—prostate gland—urinary bladder cancer	0.00106	0.0584	CbGeAlD
Alosetron—Nausea—Mitomycin—urinary bladder cancer	0.000928	0.00246	CcSEcCtD
Alosetron—Bone pain—Epirubicin—urinary bladder cancer	0.000926	0.00245	CcSEcCtD
Alosetron—Cystitis noninfective—Methotrexate—urinary bladder cancer	0.000926	0.00245	CcSEcCtD
Alosetron—Haemoglobin—Fluorouracil—urinary bladder cancer	0.000919	0.00243	CcSEcCtD
Alosetron—Cystitis—Methotrexate—urinary bladder cancer	0.000915	0.00242	CcSEcCtD
Alosetron—Haemorrhage—Fluorouracil—urinary bladder cancer	0.000915	0.00242	CcSEcCtD
Alosetron—Hypoaesthesia—Fluorouracil—urinary bladder cancer	0.00091	0.00241	CcSEcCtD
Alosetron—CYP2E1—seminal vesicle—urinary bladder cancer	0.000901	0.0494	CbGeAlD
Alosetron—Abnormal dreams—Epirubicin—urinary bladder cancer	0.000876	0.00232	CcSEcCtD
Alosetron—HTR3A—Transmembrane transport of small molecules—SLC14A2—urinary bladder cancer	0.000869	0.00794	CbGpPWpGaD
Alosetron—Ulcer—Doxorubicin—urinary bladder cancer	0.000868	0.00229	CcSEcCtD
Alosetron—Cystitis noninfective—Epirubicin—urinary bladder cancer	0.000866	0.00229	CcSEcCtD
Alosetron—Jaundice—Etoposide—urinary bladder cancer	0.000863	0.00228	CcSEcCtD
Alosetron—CYP1A2—Cytochrome P450 - arranged by substrate type—CYP4B1—urinary bladder cancer	0.000858	0.00785	CbGpPWpGaD
Alosetron—Urine output increased—Methotrexate—urinary bladder cancer	0.000857	0.00227	CcSEcCtD
Alosetron—Bladder pain—Methotrexate—urinary bladder cancer	0.000857	0.00227	CcSEcCtD
Alosetron—Bone pain—Doxorubicin—urinary bladder cancer	0.000857	0.00227	CcSEcCtD
Alosetron—Cystitis—Epirubicin—urinary bladder cancer	0.000856	0.00227	CcSEcCtD
Alosetron—Colitis—Epirubicin—urinary bladder cancer	0.000852	0.00225	CcSEcCtD
Alosetron—CYP1A2—Oxidation by Cytochrome P450—CYP4B1—urinary bladder cancer	0.000847	0.00774	CbGpPWpGaD
Alosetron—Cough—Thiotepa—urinary bladder cancer	0.00084	0.00222	CcSEcCtD
Alosetron—Hypertension—Thiotepa—urinary bladder cancer	0.000831	0.0022	CcSEcCtD
Alosetron—Arrhythmia—Gemcitabine—urinary bladder cancer	0.000831	0.0022	CcSEcCtD
Alosetron—Alopecia—Gemcitabine—urinary bladder cancer	0.000822	0.00217	CcSEcCtD
Alosetron—Myalgia—Thiotepa—urinary bladder cancer	0.00082	0.00217	CcSEcCtD
Alosetron—Arrhythmia—Fluorouracil—urinary bladder cancer	0.000817	0.00216	CcSEcCtD
Alosetron—Anxiety—Thiotepa—urinary bladder cancer	0.000817	0.00216	CcSEcCtD
Alosetron—CYP2C9—Phase 1 - Functionalization of compounds—CYP4B1—urinary bladder cancer	0.000814	0.00744	CbGpPWpGaD
Alosetron—CYP2C9—Constitutive Androstane Receptor Pathway—SMC1A—urinary bladder cancer	0.000811	0.00742	CbGpPWpGaD
Alosetron—Abnormal dreams—Doxorubicin—urinary bladder cancer	0.000811	0.00215	CcSEcCtD
Alosetron—CYP1A2—Phase II conjugation—GSTZ1—urinary bladder cancer	0.000809	0.0074	CbGpPWpGaD
Alosetron—Alopecia—Fluorouracil—urinary bladder cancer	0.000808	0.00214	CcSEcCtD
Alosetron—CYP1A2—renal system—urinary bladder cancer	0.000807	0.0442	CbGeAlD
Alosetron—Bladder pain—Epirubicin—urinary bladder cancer	0.000802	0.00212	CcSEcCtD
Alosetron—Cystitis noninfective—Doxorubicin—urinary bladder cancer	0.000802	0.00212	CcSEcCtD
Alosetron—Cystitis—Doxorubicin—urinary bladder cancer	0.000792	0.0021	CcSEcCtD
Alosetron—Confusional state—Thiotepa—urinary bladder cancer	0.000792	0.0021	CcSEcCtD
Alosetron—Hypoaesthesia—Etoposide—urinary bladder cancer	0.000791	0.00209	CcSEcCtD
Alosetron—Colitis—Doxorubicin—urinary bladder cancer	0.000788	0.00208	CcSEcCtD
Alosetron—CYP2E1—Biological oxidations—GSTZ1—urinary bladder cancer	0.000788	0.0072	CbGpPWpGaD
Alosetron—Polyuria—Methotrexate—urinary bladder cancer	0.000783	0.00207	CcSEcCtD
Alosetron—Infection—Thiotepa—urinary bladder cancer	0.000781	0.00206	CcSEcCtD
Alosetron—CYP2E1—Metapathway biotransformation—GSTZ1—urinary bladder cancer	0.000777	0.0071	CbGpPWpGaD
Alosetron—Arrhythmia—Cisplatin—urinary bladder cancer	0.000775	0.00205	CcSEcCtD
Alosetron—CYP1A2—Phase II conjugation—GSTO2—urinary bladder cancer	0.000767	0.00701	CbGpPWpGaD
Alosetron—CYP1A2—Phase II conjugation—NAT1—urinary bladder cancer	0.000767	0.00701	CbGpPWpGaD
Alosetron—Alopecia—Cisplatin—urinary bladder cancer	0.000766	0.00203	CcSEcCtD
Alosetron—Skin disorder—Thiotepa—urinary bladder cancer	0.000763	0.00202	CcSEcCtD
Alosetron—CYP1A2—Estrogen Receptor Pathway—ESR1—urinary bladder cancer	0.000753	0.00689	CbGpPWpGaD
Alosetron—Ill-defined disorder—Gemcitabine—urinary bladder cancer	0.000752	0.00199	CcSEcCtD
Alosetron—CYP2E1—Biological oxidations—GSTO2—urinary bladder cancer	0.000747	0.00683	CbGpPWpGaD
Alosetron—CYP2E1—Biological oxidations—NAT1—urinary bladder cancer	0.000747	0.00683	CbGpPWpGaD
Alosetron—CYP3A4—Estrogen metabolism—NQO1—urinary bladder cancer	0.000744	0.0068	CbGpPWpGaD
Alosetron—Flatulence—Cisplatin—urinary bladder cancer	0.000744	0.00197	CcSEcCtD
Alosetron—Bladder pain—Doxorubicin—urinary bladder cancer	0.000742	0.00196	CcSEcCtD
Alosetron—CYP1A2—Estrogen metabolism—GSTM1—urinary bladder cancer	0.000739	0.00676	CbGpPWpGaD
Alosetron—CYP2E1—Metapathway biotransformation—GSTO2—urinary bladder cancer	0.000736	0.00673	CbGpPWpGaD
Alosetron—Malaise—Gemcitabine—urinary bladder cancer	0.00073	0.00193	CcSEcCtD
Alosetron—Muscle spasms—Cisplatin—urinary bladder cancer	0.000726	0.00192	CcSEcCtD
Alosetron—CYP2E1—renal system—urinary bladder cancer	0.000726	0.0398	CbGeAlD
Alosetron—Eczema—Epirubicin—urinary bladder cancer	0.000716	0.00189	CcSEcCtD
Alosetron—Musculoskeletal discomfort—Thiotepa—urinary bladder cancer	0.000716	0.00189	CcSEcCtD
Alosetron—CYP2E1—urethra—urinary bladder cancer	0.000713	0.0391	CbGeAlD
Alosetron—Tremor—Cisplatin—urinary bladder cancer	0.000707	0.00187	CcSEcCtD
Alosetron—Cough—Gemcitabine—urinary bladder cancer	0.000707	0.00187	CcSEcCtD
Alosetron—Alopecia—Etoposide—urinary bladder cancer	0.000702	0.00186	CcSEcCtD
Alosetron—CYP1A2—Phase II conjugation—UGT2B7—urinary bladder cancer	0.000702	0.00642	CbGpPWpGaD
Alosetron—Ill-defined disorder—Cisplatin—urinary bladder cancer	0.0007	0.00185	CcSEcCtD
Alosetron—Hypertension—Gemcitabine—urinary bladder cancer	0.000699	0.00185	CcSEcCtD
Alosetron—CYP1A2—Phase 1 - Functionalization of compounds—CYP4B1—urinary bladder cancer	0.000696	0.00636	CbGpPWpGaD
Alosetron—Myalgia—Gemcitabine—urinary bladder cancer	0.00069	0.00182	CcSEcCtD
Alosetron—CYP2E1—Biological oxidations—UGT2B7—urinary bladder cancer	0.000683	0.00624	CbGpPWpGaD
Alosetron—Discomfort—Gemcitabine—urinary bladder cancer	0.000681	0.0018	CcSEcCtD
Alosetron—Malaise—Cisplatin—urinary bladder cancer	0.000681	0.0018	CcSEcCtD
Alosetron—Myalgia—Fluorouracil—urinary bladder cancer	0.000678	0.00179	CcSEcCtD
Alosetron—Fatigue—Thiotepa—urinary bladder cancer	0.000678	0.00179	CcSEcCtD
Alosetron—CYP2E1—Metapathway biotransformation—UGT2B7—urinary bladder cancer	0.000674	0.00616	CbGpPWpGaD
Alosetron—Constipation—Thiotepa—urinary bladder cancer	0.000672	0.00178	CcSEcCtD
Alosetron—Pain—Thiotepa—urinary bladder cancer	0.000672	0.00178	CcSEcCtD
Alosetron—Discomfort—Fluorouracil—urinary bladder cancer	0.00067	0.00177	CcSEcCtD
Alosetron—Muscle spasms—Etoposide—urinary bladder cancer	0.000665	0.00176	CcSEcCtD
Alosetron—Eczema—Doxorubicin—urinary bladder cancer	0.000663	0.00175	CcSEcCtD
Alosetron—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP4B1—urinary bladder cancer	0.000662	0.00606	CbGpPWpGaD
Alosetron—Hypoglycaemia—Epirubicin—urinary bladder cancer	0.00066	0.00174	CcSEcCtD
Alosetron—Infection—Gemcitabine—urinary bladder cancer	0.000657	0.00174	CcSEcCtD
Alosetron—Confusional state—Fluorouracil—urinary bladder cancer	0.000655	0.00173	CcSEcCtD
Alosetron—CYP3A4—Oxidation by Cytochrome P450—CYP4B1—urinary bladder cancer	0.000654	0.00598	CbGpPWpGaD
Alosetron—Feeling abnormal—Thiotepa—urinary bladder cancer	0.000648	0.00171	CcSEcCtD
Alosetron—Infection—Fluorouracil—urinary bladder cancer	0.000646	0.00171	CcSEcCtD
Alosetron—Myalgia—Cisplatin—urinary bladder cancer	0.000643	0.0017	CcSEcCtD
Alosetron—Skin disorder—Gemcitabine—urinary bladder cancer	0.000642	0.0017	CcSEcCtD
Alosetron—Ill-defined disorder—Etoposide—urinary bladder cancer	0.000642	0.0017	CcSEcCtD
Alosetron—Anxiety—Cisplatin—urinary bladder cancer	0.000641	0.00169	CcSEcCtD
Alosetron—Hyperhidrosis—Gemcitabine—urinary bladder cancer	0.000639	0.00169	CcSEcCtD
Alosetron—Discomfort—Cisplatin—urinary bladder cancer	0.000635	0.00168	CcSEcCtD
Alosetron—HTR3A—Transmembrane transport of small molecules—AQP3—urinary bladder cancer	0.000628	0.00574	CbGpPWpGaD
Alosetron—Urticaria—Thiotepa—urinary bladder cancer	0.000624	0.00165	CcSEcCtD
Alosetron—Malaise—Etoposide—urinary bladder cancer	0.000624	0.00165	CcSEcCtD
Alosetron—CYP2C9—Arachidonic acid metabolism—HPGDS—urinary bladder cancer	0.000618	0.00565	CbGpPWpGaD
Alosetron—CYP2E1—Biological oxidations—CYP4B1—urinary bladder cancer	0.000615	0.00562	CbGpPWpGaD
Alosetron—CYP2C9—female reproductive system—urinary bladder cancer	0.000613	0.0336	CbGeAlD
Alosetron—Infection—Cisplatin—urinary bladder cancer	0.000612	0.00162	CcSEcCtD
Alosetron—Hypoglycaemia—Doxorubicin—urinary bladder cancer	0.00061	0.00161	CcSEcCtD
Alosetron—CYP2E1—Metapathway biotransformation—CYP4B1—urinary bladder cancer	0.000606	0.00554	CbGpPWpGaD
Alosetron—Cough—Etoposide—urinary bladder cancer	0.000604	0.0016	CcSEcCtD
Alosetron—Musculoskeletal discomfort—Gemcitabine—urinary bladder cancer	0.000602	0.00159	CcSEcCtD
Alosetron—Skin disorder—Cisplatin—urinary bladder cancer	0.000598	0.00158	CcSEcCtD
Alosetron—Hypertension—Etoposide—urinary bladder cancer	0.000597	0.00158	CcSEcCtD
Alosetron—Hyperhidrosis—Cisplatin—urinary bladder cancer	0.000596	0.00158	CcSEcCtD
Alosetron—Musculoskeletal discomfort—Fluorouracil—urinary bladder cancer	0.000592	0.00157	CcSEcCtD
Alosetron—Abdominal pain upper—Epirubicin—urinary bladder cancer	0.000588	0.00156	CcSEcCtD
Alosetron—CYP3A4—renal system—urinary bladder cancer	0.000584	0.032	CbGeAlD
Alosetron—Discomfort—Etoposide—urinary bladder cancer	0.000582	0.00154	CcSEcCtD
Alosetron—CYP2E1—female reproductive system—urinary bladder cancer	0.000581	0.0319	CbGeAlD
Alosetron—Hypersensitivity—Thiotepa—urinary bladder cancer	0.000579	0.00153	CcSEcCtD
Alosetron—Nasopharyngitis—Epirubicin—urinary bladder cancer	0.000576	0.00152	CcSEcCtD
Alosetron—CYP3A4—Estrogen metabolism—GSTM1—urinary bladder cancer	0.00057	0.00521	CbGpPWpGaD
Alosetron—Abdominal discomfort—Methotrexate—urinary bladder cancer	0.00057	0.00151	CcSEcCtD
Alosetron—Fatigue—Gemcitabine—urinary bladder cancer	0.00057	0.00151	CcSEcCtD
Alosetron—Gastritis—Epirubicin—urinary bladder cancer	0.00057	0.00151	CcSEcCtD
Alosetron—Confusional state—Etoposide—urinary bladder cancer	0.000569	0.00151	CcSEcCtD
Alosetron—Alanine aminotransferase increased—Epirubicin—urinary bladder cancer	0.000568	0.0015	CcSEcCtD
Alosetron—Pain—Gemcitabine—urinary bladder cancer	0.000565	0.0015	CcSEcCtD
Alosetron—Constipation—Gemcitabine—urinary bladder cancer	0.000565	0.0015	CcSEcCtD
Alosetron—CYP1A2—Aryl Hydrocarbon Receptor—HPGDS—urinary bladder cancer	0.000565	0.00516	CbGpPWpGaD
Alosetron—Asthenia—Thiotepa—urinary bladder cancer	0.000564	0.00149	CcSEcCtD
Alosetron—Musculoskeletal discomfort—Cisplatin—urinary bladder cancer	0.000561	0.00148	CcSEcCtD
Alosetron—Infection—Etoposide—urinary bladder cancer	0.000561	0.00148	CcSEcCtD
Alosetron—Abdominal distension—Epirubicin—urinary bladder cancer	0.00056	0.00148	CcSEcCtD
Alosetron—Pain—Fluorouracil—urinary bladder cancer	0.000556	0.00147	CcSEcCtD
Alosetron—CYP2C9—Biological oxidations—GSTZ1—urinary bladder cancer	0.000554	0.00507	CbGpPWpGaD
Alosetron—Upper respiratory tract infection—Methotrexate—urinary bladder cancer	0.000553	0.00146	CcSEcCtD
Alosetron—Skin disorder—Etoposide—urinary bladder cancer	0.000548	0.00145	CcSEcCtD
Alosetron—CYP2C9—Metapathway biotransformation—GSTZ1—urinary bladder cancer	0.000546	0.005	CbGpPWpGaD
Alosetron—Hyperhidrosis—Etoposide—urinary bladder cancer	0.000546	0.00144	CcSEcCtD
Alosetron—Feeling abnormal—Gemcitabine—urinary bladder cancer	0.000545	0.00144	CcSEcCtD
Alosetron—Abdominal pain upper—Doxorubicin—urinary bladder cancer	0.000544	0.00144	CcSEcCtD
Alosetron—CYP3A4—Phase 1 - Functionalization of compounds—CYP4B1—urinary bladder cancer	0.000537	0.00491	CbGpPWpGaD
Alosetron—Feeling abnormal—Fluorouracil—urinary bladder cancer	0.000536	0.00142	CcSEcCtD
Alosetron—CYP3A4—Constitutive Androstane Receptor Pathway—SMC1A—urinary bladder cancer	0.000535	0.00489	CbGpPWpGaD
Alosetron—Nasopharyngitis—Doxorubicin—urinary bladder cancer	0.000533	0.00141	CcSEcCtD
Alosetron—CYP2E1—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—urinary bladder cancer	0.00053	0.00484	CbGpPWpGaD
Alosetron—Depression—Methotrexate—urinary bladder cancer	0.000529	0.0014	CcSEcCtD
Alosetron—CYP1A2—Arachidonic acid metabolism—HPGDS—urinary bladder cancer	0.000528	0.00483	CbGpPWpGaD
Alosetron—Gastritis—Doxorubicin—urinary bladder cancer	0.000527	0.00139	CcSEcCtD
Alosetron—Pain—Cisplatin—urinary bladder cancer	0.000527	0.00139	CcSEcCtD
Alosetron—Alanine aminotransferase increased—Doxorubicin—urinary bladder cancer	0.000525	0.00139	CcSEcCtD
Alosetron—CYP2C9—Biological oxidations—NAT1—urinary bladder cancer	0.000525	0.0048	CbGpPWpGaD
Alosetron—CYP2C9—Biological oxidations—GSTO2—urinary bladder cancer	0.000525	0.0048	CbGpPWpGaD
Alosetron—Abdominal distension—Doxorubicin—urinary bladder cancer	0.000518	0.00137	CcSEcCtD
Alosetron—CYP2C9—Metapathway biotransformation—GSTO2—urinary bladder cancer	0.000518	0.00474	CbGpPWpGaD
Alosetron—Upper respiratory tract infection—Epirubicin—urinary bladder cancer	0.000517	0.00137	CcSEcCtD
Alosetron—Urticaria—Fluorouracil—urinary bladder cancer	0.000516	0.00137	CcSEcCtD
Alosetron—Pollakiuria—Epirubicin—urinary bladder cancer	0.000514	0.00136	CcSEcCtD
Alosetron—HTR3A—Transmembrane transport of small molecules—TRPV1—urinary bladder cancer	0.000512	0.00468	CbGpPWpGaD
Alosetron—Sweating—Methotrexate—urinary bladder cancer	0.000508	0.00134	CcSEcCtD
Alosetron—Feeling abnormal—Cisplatin—urinary bladder cancer	0.000508	0.00134	CcSEcCtD
Alosetron—Hyperglycaemia—Epirubicin—urinary bladder cancer	0.000502	0.00133	CcSEcCtD
Alosetron—Vomiting—Thiotepa—urinary bladder cancer	0.0005	0.00132	CcSEcCtD
Alosetron—Rash—Thiotepa—urinary bladder cancer	0.000495	0.00131	CcSEcCtD
Alosetron—Dermatitis—Thiotepa—urinary bladder cancer	0.000495	0.00131	CcSEcCtD
Alosetron—Headache—Thiotepa—urinary bladder cancer	0.000492	0.0013	CcSEcCtD
Alosetron—Fatigue—Etoposide—urinary bladder cancer	0.000487	0.00129	CcSEcCtD
Alosetron—Jaundice—Epirubicin—urinary bladder cancer	0.000484	0.00128	CcSEcCtD
Alosetron—Constipation—Etoposide—urinary bladder cancer	0.000483	0.00128	CcSEcCtD
Alosetron—Pain—Etoposide—urinary bladder cancer	0.000483	0.00128	CcSEcCtD
Alosetron—Urinary tract infection—Epirubicin—urinary bladder cancer	0.000482	0.00128	CcSEcCtD
Alosetron—CYP2C9—Biological oxidations—UGT2B7—urinary bladder cancer	0.00048	0.00439	CbGpPWpGaD
Alosetron—HTR3A—SIDS Susceptibility Pathways—CREBBP—urinary bladder cancer	0.000479	0.00438	CbGpPWpGaD
Alosetron—Hypersensitivity—Fluorouracil—urinary bladder cancer	0.000479	0.00127	CcSEcCtD
Alosetron—Upper respiratory tract infection—Doxorubicin—urinary bladder cancer	0.000478	0.00127	CcSEcCtD
Alosetron—Haemoglobin—Methotrexate—urinary bladder cancer	0.000478	0.00127	CcSEcCtD
Alosetron—Haemorrhage—Methotrexate—urinary bladder cancer	0.000476	0.00126	CcSEcCtD
Alosetron—Hepatitis—Methotrexate—urinary bladder cancer	0.000476	0.00126	CcSEcCtD
Alosetron—Sweating—Epirubicin—urinary bladder cancer	0.000476	0.00126	CcSEcCtD
Alosetron—Pollakiuria—Doxorubicin—urinary bladder cancer	0.000476	0.00126	CcSEcCtD
Alosetron—Asthenia—Gemcitabine—urinary bladder cancer	0.000474	0.00125	CcSEcCtD
Alosetron—CYP2C9—Metapathway biotransformation—UGT2B7—urinary bladder cancer	0.000474	0.00433	CbGpPWpGaD
Alosetron—CYP1A2—Biological oxidations—GSTZ1—urinary bladder cancer	0.000473	0.00433	CbGpPWpGaD
Alosetron—CYP3A4—female reproductive system—urinary bladder cancer	0.000468	0.0256	CbGeAlD
Alosetron—CYP1A2—Metapathway biotransformation—GSTZ1—urinary bladder cancer	0.000467	0.00427	CbGpPWpGaD
Alosetron—Nausea—Thiotepa—urinary bladder cancer	0.000467	0.00123	CcSEcCtD
Alosetron—Sinusitis—Epirubicin—urinary bladder cancer	0.000465	0.00123	CcSEcCtD
Alosetron—Feeling abnormal—Etoposide—urinary bladder cancer	0.000465	0.00123	CcSEcCtD
Alosetron—Hyperglycaemia—Doxorubicin—urinary bladder cancer	0.000464	0.00123	CcSEcCtD
Alosetron—CYP1A2—Aryl Hydrocarbon Receptor—NQO1—urinary bladder cancer	0.000455	0.00416	CbGpPWpGaD
Alosetron—CYP1A2—Aryl Hydrocarbon Receptor Pathway—NQO1—urinary bladder cancer	0.000455	0.00416	CbGpPWpGaD
Alosetron—Hypersensitivity—Cisplatin—urinary bladder cancer	0.000454	0.0012	CcSEcCtD
Alosetron—CYP1A2—Biological oxidations—GSTO2—urinary bladder cancer	0.000449	0.0041	CbGpPWpGaD
Alosetron—CYP1A2—Biological oxidations—NAT1—urinary bladder cancer	0.000449	0.0041	CbGpPWpGaD
Alosetron—Urticaria—Etoposide—urinary bladder cancer	0.000448	0.00119	CcSEcCtD
Alosetron—Haemoglobin—Epirubicin—urinary bladder cancer	0.000448	0.00118	CcSEcCtD
Alosetron—Jaundice—Doxorubicin—urinary bladder cancer	0.000447	0.00118	CcSEcCtD
Alosetron—Urinary tract infection—Doxorubicin—urinary bladder cancer	0.000446	0.00118	CcSEcCtD
Alosetron—Hepatitis—Epirubicin—urinary bladder cancer	0.000445	0.00118	CcSEcCtD
Alosetron—Haemorrhage—Epirubicin—urinary bladder cancer	0.000445	0.00118	CcSEcCtD
Alosetron—Hypoaesthesia—Epirubicin—urinary bladder cancer	0.000443	0.00117	CcSEcCtD
Alosetron—CYP1A2—Metapathway biotransformation—GSTO2—urinary bladder cancer	0.000443	0.00405	CbGpPWpGaD
Alosetron—Asthenia—Cisplatin—urinary bladder cancer	0.000442	0.00117	CcSEcCtD
Alosetron—Sweating—Doxorubicin—urinary bladder cancer	0.00044	0.00116	CcSEcCtD
Alosetron—CYP2C9—Biological oxidations—CYP4B1—urinary bladder cancer	0.000433	0.00395	CbGpPWpGaD
Alosetron—Sinusitis—Doxorubicin—urinary bladder cancer	0.000431	0.00114	CcSEcCtD
Alosetron—CYP2C9—Metapathway biotransformation—CYP4B1—urinary bladder cancer	0.000427	0.0039	CbGpPWpGaD
Alosetron—Alopecia—Methotrexate—urinary bladder cancer	0.000421	0.00111	CcSEcCtD
Alosetron—CYP1A2—Phase II conjugation—NAT2—urinary bladder cancer	0.00042	0.00384	CbGpPWpGaD
Alosetron—Vomiting—Gemcitabine—urinary bladder cancer	0.00042	0.00111	CcSEcCtD
Alosetron—Rash—Gemcitabine—urinary bladder cancer	0.000417	0.0011	CcSEcCtD
Alosetron—Dermatitis—Gemcitabine—urinary bladder cancer	0.000416	0.0011	CcSEcCtD
Alosetron—Hypersensitivity—Etoposide—urinary bladder cancer	0.000416	0.0011	CcSEcCtD
Alosetron—Haemoglobin—Doxorubicin—urinary bladder cancer	0.000414	0.0011	CcSEcCtD
Alosetron—Headache—Gemcitabine—urinary bladder cancer	0.000414	0.0011	CcSEcCtD
Alosetron—Vomiting—Fluorouracil—urinary bladder cancer	0.000413	0.00109	CcSEcCtD
Alosetron—Haemorrhage—Doxorubicin—urinary bladder cancer	0.000412	0.00109	CcSEcCtD
Alosetron—Hepatitis—Doxorubicin—urinary bladder cancer	0.000412	0.00109	CcSEcCtD
Alosetron—CYP1A2—Biological oxidations—UGT2B7—urinary bladder cancer	0.000411	0.00375	CbGpPWpGaD
Alosetron—Hypoaesthesia—Doxorubicin—urinary bladder cancer	0.00041	0.00108	CcSEcCtD
Alosetron—Rash—Fluorouracil—urinary bladder cancer	0.00041	0.00108	CcSEcCtD
Alosetron—Dermatitis—Fluorouracil—urinary bladder cancer	0.000409	0.00108	CcSEcCtD
Alosetron—CYP2E1—Biological oxidations—NAT2—urinary bladder cancer	0.000409	0.00374	CbGpPWpGaD
Alosetron—Headache—Fluorouracil—urinary bladder cancer	0.000407	0.00108	CcSEcCtD
Alosetron—Asthenia—Etoposide—urinary bladder cancer	0.000405	0.00107	CcSEcCtD
Alosetron—CYP1A2—Metapathway biotransformation—UGT2B7—urinary bladder cancer	0.000405	0.0037	CbGpPWpGaD
Alosetron—CYP2E1—Metapathway biotransformation—NAT2—urinary bladder cancer	0.000403	0.00369	CbGpPWpGaD
Alosetron—Arrhythmia—Epirubicin—urinary bladder cancer	0.000398	0.00105	CcSEcCtD
Alosetron—Alopecia—Epirubicin—urinary bladder cancer	0.000394	0.00104	CcSEcCtD
Alosetron—Nausea—Gemcitabine—urinary bladder cancer	0.000393	0.00104	CcSEcCtD
Alosetron—Vomiting—Cisplatin—urinary bladder cancer	0.000392	0.00104	CcSEcCtD
Alosetron—Rash—Cisplatin—urinary bladder cancer	0.000388	0.00103	CcSEcCtD
Alosetron—Dermatitis—Cisplatin—urinary bladder cancer	0.000388	0.00103	CcSEcCtD
Alosetron—Nausea—Fluorouracil—urinary bladder cancer	0.000386	0.00102	CcSEcCtD
Alosetron—Ill-defined disorder—Methotrexate—urinary bladder cancer	0.000384	0.00102	CcSEcCtD
Alosetron—Flatulence—Epirubicin—urinary bladder cancer	0.000382	0.00101	CcSEcCtD
Alosetron—HTR3A—SIDS Susceptibility Pathways—CXCL8—urinary bladder cancer	0.000381	0.00348	CbGpPWpGaD
Alosetron—Malaise—Methotrexate—urinary bladder cancer	0.000374	0.000988	CcSEcCtD
Alosetron—Muscle spasms—Epirubicin—urinary bladder cancer	0.000373	0.000986	CcSEcCtD
Alosetron—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—urinary bladder cancer	0.000373	0.00341	CbGpPWpGaD
Alosetron—CYP1A2—Biological oxidations—CYP4B1—urinary bladder cancer	0.00037	0.00338	CbGpPWpGaD
Alosetron—Arrhythmia—Doxorubicin—urinary bladder cancer	0.000368	0.000974	CcSEcCtD
Alosetron—Nausea—Cisplatin—urinary bladder cancer	0.000366	0.000968	CcSEcCtD
Alosetron—CYP2C9—Arachidonic acid metabolism—GPX1—urinary bladder cancer	0.000366	0.00334	CbGpPWpGaD
Alosetron—CYP3A4—Biological oxidations—GSTZ1—urinary bladder cancer	0.000365	0.00334	CbGpPWpGaD
Alosetron—CYP1A2—Metapathway biotransformation—CYP4B1—urinary bladder cancer	0.000365	0.00333	CbGpPWpGaD
Alosetron—Alopecia—Doxorubicin—urinary bladder cancer	0.000364	0.000963	CcSEcCtD
Alosetron—Cough—Methotrexate—urinary bladder cancer	0.000362	0.000956	CcSEcCtD
Alosetron—CYP3A4—Metapathway biotransformation—GSTZ1—urinary bladder cancer	0.00036	0.00329	CbGpPWpGaD
Alosetron—Ill-defined disorder—Epirubicin—urinary bladder cancer	0.00036	0.000951	CcSEcCtD
Alosetron—Vomiting—Etoposide—urinary bladder cancer	0.000359	0.000949	CcSEcCtD
Alosetron—Rash—Etoposide—urinary bladder cancer	0.000356	0.000941	CcSEcCtD
Alosetron—Dermatitis—Etoposide—urinary bladder cancer	0.000356	0.000941	CcSEcCtD
Alosetron—Headache—Etoposide—urinary bladder cancer	0.000354	0.000935	CcSEcCtD
Alosetron—Flatulence—Doxorubicin—urinary bladder cancer	0.000353	0.000935	CcSEcCtD
Alosetron—Myalgia—Methotrexate—urinary bladder cancer	0.000353	0.000933	CcSEcCtD
Alosetron—Malaise—Epirubicin—urinary bladder cancer	0.00035	0.000925	CcSEcCtD
Alosetron—Discomfort—Methotrexate—urinary bladder cancer	0.000348	0.000922	CcSEcCtD
Alosetron—CYP3A4—Biological oxidations—GSTO2—urinary bladder cancer	0.000346	0.00317	CbGpPWpGaD
Alosetron—CYP3A4—Biological oxidations—NAT1—urinary bladder cancer	0.000346	0.00317	CbGpPWpGaD
Alosetron—HTR3A—Transmembrane transport of small molecules—TFRC—urinary bladder cancer	0.000346	0.00316	CbGpPWpGaD
Alosetron—Muscle spasms—Doxorubicin—urinary bladder cancer	0.000345	0.000912	CcSEcCtD
Alosetron—CYP3A4—Metapathway biotransformation—GSTO2—urinary bladder cancer	0.000342	0.00312	CbGpPWpGaD
Alosetron—Confusional state—Methotrexate—urinary bladder cancer	0.000341	0.000902	CcSEcCtD
Alosetron—Cough—Epirubicin—urinary bladder cancer	0.000338	0.000895	CcSEcCtD
Alosetron—CYP1A2—Phase II conjugation—HPGDS—urinary bladder cancer	0.000336	0.00307	CbGpPWpGaD
Alosetron—Infection—Methotrexate—urinary bladder cancer	0.000336	0.000888	CcSEcCtD
Alosetron—Nausea—Etoposide—urinary bladder cancer	0.000335	0.000887	CcSEcCtD
Alosetron—Hypertension—Epirubicin—urinary bladder cancer	0.000335	0.000885	CcSEcCtD
Alosetron—Ill-defined disorder—Doxorubicin—urinary bladder cancer	0.000333	0.00088	CcSEcCtD
Alosetron—Myalgia—Epirubicin—urinary bladder cancer	0.00033	0.000873	CcSEcCtD
Alosetron—Anxiety—Epirubicin—urinary bladder cancer	0.000329	0.00087	CcSEcCtD
Alosetron—Skin disorder—Methotrexate—urinary bladder cancer	0.000328	0.000869	CcSEcCtD
Alosetron—CYP2E1—Biological oxidations—HPGDS—urinary bladder cancer	0.000327	0.00299	CbGpPWpGaD
Alosetron—Hyperhidrosis—Methotrexate—urinary bladder cancer	0.000327	0.000865	CcSEcCtD
Alosetron—HTR3A—SIDS Susceptibility Pathways—EP300—urinary bladder cancer	0.000326	0.00298	CbGpPWpGaD
Alosetron—Discomfort—Epirubicin—urinary bladder cancer	0.000326	0.000863	CcSEcCtD
Alosetron—CYP1A2—Phase II conjugation—GSTT1—urinary bladder cancer	0.000326	0.00298	CbGpPWpGaD
Alosetron—Malaise—Doxorubicin—urinary bladder cancer	0.000323	0.000856	CcSEcCtD
Alosetron—Dry mouth—Epirubicin—urinary bladder cancer	0.000323	0.000854	CcSEcCtD
Alosetron—Confusional state—Epirubicin—urinary bladder cancer	0.000319	0.000844	CcSEcCtD
Alosetron—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—urinary bladder cancer	0.000318	0.00291	CbGpPWpGaD
Alosetron—CYP2E1—Biological oxidations—GSTT1—urinary bladder cancer	0.000317	0.0029	CbGpPWpGaD
Alosetron—CYP3A4—Biological oxidations—UGT2B7—urinary bladder cancer	0.000317	0.0029	CbGpPWpGaD
Alosetron—Infection—Epirubicin—urinary bladder cancer	0.000314	0.000831	CcSEcCtD
Alosetron—Cough—Doxorubicin—urinary bladder cancer	0.000313	0.000828	CcSEcCtD
Alosetron—CYP1A2—Arachidonic acid metabolism—GPX1—urinary bladder cancer	0.000313	0.00286	CbGpPWpGaD
Alosetron—CYP3A4—Metapathway biotransformation—UGT2B7—urinary bladder cancer	0.000312	0.00286	CbGpPWpGaD
Alosetron—Hypertension—Doxorubicin—urinary bladder cancer	0.00031	0.000819	CcSEcCtD
Alosetron—Musculoskeletal discomfort—Methotrexate—urinary bladder cancer	0.000308	0.000815	CcSEcCtD
Alosetron—Skin disorder—Epirubicin—urinary bladder cancer	0.000307	0.000813	CcSEcCtD
Alosetron—Hyperhidrosis—Epirubicin—urinary bladder cancer	0.000306	0.000809	CcSEcCtD
Alosetron—Myalgia—Doxorubicin—urinary bladder cancer	0.000305	0.000808	CcSEcCtD
Alosetron—Anxiety—Doxorubicin—urinary bladder cancer	0.000304	0.000805	CcSEcCtD
Alosetron—Discomfort—Doxorubicin—urinary bladder cancer	0.000302	0.000798	CcSEcCtD
Alosetron—Dry mouth—Doxorubicin—urinary bladder cancer	0.000299	0.00079	CcSEcCtD
Alosetron—Confusional state—Doxorubicin—urinary bladder cancer	0.000295	0.000781	CcSEcCtD
Alosetron—Fatigue—Methotrexate—urinary bladder cancer	0.000292	0.000771	CcSEcCtD
Alosetron—Infection—Doxorubicin—urinary bladder cancer	0.000291	0.000769	CcSEcCtD
Alosetron—Pain—Methotrexate—urinary bladder cancer	0.000289	0.000765	CcSEcCtD
Alosetron—Musculoskeletal discomfort—Epirubicin—urinary bladder cancer	0.000288	0.000763	CcSEcCtD
Alosetron—CYP2C9—Biological oxidations—NAT2—urinary bladder cancer	0.000288	0.00263	CbGpPWpGaD
Alosetron—CYP3A4—Biological oxidations—CYP4B1—urinary bladder cancer	0.000285	0.00261	CbGpPWpGaD
Alosetron—Skin disorder—Doxorubicin—urinary bladder cancer	0.000284	0.000752	CcSEcCtD
Alosetron—CYP2C9—Metapathway biotransformation—NAT2—urinary bladder cancer	0.000284	0.0026	CbGpPWpGaD
Alosetron—Hyperhidrosis—Doxorubicin—urinary bladder cancer	0.000283	0.000749	CcSEcCtD
Alosetron—CYP3A4—Metapathway biotransformation—CYP4B1—urinary bladder cancer	0.000281	0.00257	CbGpPWpGaD
Alosetron—Feeling abnormal—Methotrexate—urinary bladder cancer	0.000279	0.000737	CcSEcCtD
Alosetron—CYP1A2—Aryl Hydrocarbon Receptor—ESR1—urinary bladder cancer	0.000274	0.00251	CbGpPWpGaD
Alosetron—Fatigue—Epirubicin—urinary bladder cancer	0.000273	0.000722	CcSEcCtD
Alosetron—Pain—Epirubicin—urinary bladder cancer	0.000271	0.000716	CcSEcCtD
Alosetron—Constipation—Epirubicin—urinary bladder cancer	0.000271	0.000716	CcSEcCtD
Alosetron—Urticaria—Methotrexate—urinary bladder cancer	0.000269	0.00071	CcSEcCtD
Alosetron—Musculoskeletal discomfort—Doxorubicin—urinary bladder cancer	0.000267	0.000706	CcSEcCtD
Alosetron—HTR3A—SIDS Susceptibility Pathways—TNF—urinary bladder cancer	0.000265	0.00242	CbGpPWpGaD
Alosetron—Feeling abnormal—Epirubicin—urinary bladder cancer	0.000261	0.00069	CcSEcCtD
Alosetron—Fatigue—Doxorubicin—urinary bladder cancer	0.000252	0.000668	CcSEcCtD
Alosetron—Urticaria—Epirubicin—urinary bladder cancer	0.000251	0.000665	CcSEcCtD
Alosetron—Pain—Doxorubicin—urinary bladder cancer	0.00025	0.000662	CcSEcCtD
Alosetron—Constipation—Doxorubicin—urinary bladder cancer	0.00025	0.000662	CcSEcCtD
Alosetron—Hypersensitivity—Methotrexate—urinary bladder cancer	0.000249	0.000659	CcSEcCtD
Alosetron—CYP1A2—Biological oxidations—NAT2—urinary bladder cancer	0.000246	0.00225	CbGpPWpGaD
Alosetron—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—urinary bladder cancer	0.000246	0.00225	CbGpPWpGaD
Alosetron—Asthenia—Methotrexate—urinary bladder cancer	0.000243	0.000642	CcSEcCtD
Alosetron—CYP1A2—Metapathway biotransformation—NAT2—urinary bladder cancer	0.000243	0.00222	CbGpPWpGaD
Alosetron—Feeling abnormal—Doxorubicin—urinary bladder cancer	0.000241	0.000638	CcSEcCtD
Alosetron—CYP1A2—Aryl Hydrocarbon Receptor—RB1—urinary bladder cancer	0.000239	0.00219	CbGpPWpGaD
Alosetron—Hypersensitivity—Epirubicin—urinary bladder cancer	0.000233	0.000617	CcSEcCtD
Alosetron—Urticaria—Doxorubicin—urinary bladder cancer	0.000233	0.000615	CcSEcCtD
Alosetron—CYP2C9—Biological oxidations—HPGDS—urinary bladder cancer	0.00023	0.0021	CbGpPWpGaD
Alosetron—Asthenia—Epirubicin—urinary bladder cancer	0.000227	0.0006	CcSEcCtD
Alosetron—CYP1A2—Phase II conjugation—GSTP1—urinary bladder cancer	0.000226	0.00207	CbGpPWpGaD
Alosetron—CYP2C9—Biological oxidations—GSTT1—urinary bladder cancer	0.000223	0.00204	CbGpPWpGaD
Alosetron—CYP2E1—Biological oxidations—GSTP1—urinary bladder cancer	0.00022	0.00201	CbGpPWpGaD
Alosetron—CYP2E1—Metapathway biotransformation—GSTP1—urinary bladder cancer	0.000217	0.00198	CbGpPWpGaD
Alosetron—Hypersensitivity—Doxorubicin—urinary bladder cancer	0.000216	0.000571	CcSEcCtD
Alosetron—CYP2C9—Arachidonic acid metabolism—PTGS2—urinary bladder cancer	0.000215	0.00197	CbGpPWpGaD
Alosetron—Vomiting—Methotrexate—urinary bladder cancer	0.000215	0.000569	CcSEcCtD
Alosetron—Rash—Methotrexate—urinary bladder cancer	0.000213	0.000564	CcSEcCtD
Alosetron—Dermatitis—Methotrexate—urinary bladder cancer	0.000213	0.000563	CcSEcCtD
Alosetron—Headache—Methotrexate—urinary bladder cancer	0.000212	0.00056	CcSEcCtD
Alosetron—Asthenia—Doxorubicin—urinary bladder cancer	0.00021	0.000556	CcSEcCtD
Alosetron—CYP1A2—Phase II conjugation—GSTM1—urinary bladder cancer	0.000208	0.0019	CbGpPWpGaD
Alosetron—CYP2E1—Biological oxidations—GSTM1—urinary bladder cancer	0.000202	0.00185	CbGpPWpGaD
Alosetron—Vomiting—Epirubicin—urinary bladder cancer	0.000201	0.000532	CcSEcCtD
Alosetron—Nausea—Methotrexate—urinary bladder cancer	0.000201	0.000531	CcSEcCtD
Alosetron—Rash—Epirubicin—urinary bladder cancer	0.0002	0.000528	CcSEcCtD
Alosetron—Dermatitis—Epirubicin—urinary bladder cancer	0.000199	0.000527	CcSEcCtD
Alosetron—CYP2E1—Metapathway biotransformation—GSTM1—urinary bladder cancer	0.000199	0.00182	CbGpPWpGaD
Alosetron—Headache—Epirubicin—urinary bladder cancer	0.000198	0.000524	CcSEcCtD
Alosetron—CYP1A2—Aryl Hydrocarbon Receptor—PTGS2—urinary bladder cancer	0.000197	0.0018	CbGpPWpGaD
Alosetron—CYP1A2—Biological oxidations—HPGDS—urinary bladder cancer	0.000197	0.0018	CbGpPWpGaD
Alosetron—CYP1A2—Biological oxidations—GSTT1—urinary bladder cancer	0.000191	0.00174	CbGpPWpGaD
Alosetron—CYP3A4—Biological oxidations—NAT2—urinary bladder cancer	0.00019	0.00174	CbGpPWpGaD
Alosetron—Nausea—Epirubicin—urinary bladder cancer	0.000188	0.000497	CcSEcCtD
Alosetron—CYP3A4—Metapathway biotransformation—NAT2—urinary bladder cancer	0.000187	0.00171	CbGpPWpGaD
Alosetron—Vomiting—Doxorubicin—urinary bladder cancer	0.000186	0.000492	CcSEcCtD
Alosetron—Rash—Doxorubicin—urinary bladder cancer	0.000185	0.000488	CcSEcCtD
Alosetron—Dermatitis—Doxorubicin—urinary bladder cancer	0.000184	0.000488	CcSEcCtD
Alosetron—CYP1A2—Arachidonic acid metabolism—PTGS2—urinary bladder cancer	0.000184	0.00168	CbGpPWpGaD
Alosetron—Headache—Doxorubicin—urinary bladder cancer	0.000183	0.000485	CcSEcCtD
Alosetron—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL2—urinary bladder cancer	0.000182	0.00167	CbGpPWpGaD
Alosetron—Nausea—Doxorubicin—urinary bladder cancer	0.000174	0.00046	CcSEcCtD
Alosetron—CYP1A2—Aryl Hydrocarbon Receptor—CDKN1A—urinary bladder cancer	0.000172	0.00157	CbGpPWpGaD
Alosetron—CYP2C9—Metabolism of lipids and lipoproteins—CYP4B1—urinary bladder cancer	0.000166	0.00152	CbGpPWpGaD
Alosetron—CYP1A2—Aryl Hydrocarbon Receptor—EP300—urinary bladder cancer	0.000164	0.0015	CbGpPWpGaD
Alosetron—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EP300—urinary bladder cancer	0.000164	0.0015	CbGpPWpGaD
Alosetron—HTR3A—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	0.000162	0.00148	CbGpPWpGaD
Alosetron—CYP1A2—Aryl Hydrocarbon Receptor Pathway—SRC—urinary bladder cancer	0.000159	0.00145	CbGpPWpGaD
Alosetron—CYP1A2—Aryl Hydrocarbon Receptor—SRC—urinary bladder cancer	0.000159	0.00145	CbGpPWpGaD
Alosetron—CYP2C9—Biological oxidations—GSTP1—urinary bladder cancer	0.000155	0.00141	CbGpPWpGaD
Alosetron—CYP2C9—Metapathway biotransformation—GSTP1—urinary bladder cancer	0.000153	0.00139	CbGpPWpGaD
Alosetron—CYP3A4—Biological oxidations—HPGDS—urinary bladder cancer	0.000152	0.00139	CbGpPWpGaD
Alosetron—CYP3A4—Biological oxidations—GSTT1—urinary bladder cancer	0.000147	0.00135	CbGpPWpGaD
Alosetron—CYP1A2—Aryl Hydrocarbon Receptor—MYC—urinary bladder cancer	0.000143	0.0013	CbGpPWpGaD
Alosetron—CYP2C9—Biological oxidations—GSTM1—urinary bladder cancer	0.000142	0.0013	CbGpPWpGaD
Alosetron—CYP1A2—Metabolism of lipids and lipoproteins—CYP4B1—urinary bladder cancer	0.000142	0.0013	CbGpPWpGaD
Alosetron—CYP2C9—Metapathway biotransformation—GSTM1—urinary bladder cancer	0.00014	0.00128	CbGpPWpGaD
Alosetron—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EGFR—urinary bladder cancer	0.000139	0.00127	CbGpPWpGaD
Alosetron—CYP1A2—Aryl Hydrocarbon Receptor—EGFR—urinary bladder cancer	0.000139	0.00127	CbGpPWpGaD
Alosetron—CYP2E1—Metabolism—GSTZ1—urinary bladder cancer	0.000135	0.00123	CbGpPWpGaD
Alosetron—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—urinary bladder cancer	0.000133	0.00121	CbGpPWpGaD
Alosetron—CYP1A2—Aryl Hydrocarbon Receptor—TNF—urinary bladder cancer	0.000133	0.00121	CbGpPWpGaD
Alosetron—CYP1A2—Biological oxidations—GSTP1—urinary bladder cancer	0.000132	0.00121	CbGpPWpGaD
Alosetron—CYP1A2—Aryl Hydrocarbon Receptor—KRAS—urinary bladder cancer	0.000132	0.0012	CbGpPWpGaD
Alosetron—CYP1A2—Metapathway biotransformation—GSTP1—urinary bladder cancer	0.00013	0.00119	CbGpPWpGaD
Alosetron—CYP2E1—Metabolism—GSTO2—urinary bladder cancer	0.000128	0.00117	CbGpPWpGaD
Alosetron—CYP2E1—Metabolism—NAT1—urinary bladder cancer	0.000128	0.00117	CbGpPWpGaD
Alosetron—CYP1A2—Biological oxidations—GSTM1—urinary bladder cancer	0.000121	0.00111	CbGpPWpGaD
Alosetron—CYP1A2—Metapathway biotransformation—GSTM1—urinary bladder cancer	0.00012	0.0011	CbGpPWpGaD
Alosetron—CYP2E1—Metabolism—UGT2B7—urinary bladder cancer	0.000117	0.00107	CbGpPWpGaD
Alosetron—CYP1A2—Aryl Hydrocarbon Receptor—HRAS—urinary bladder cancer	0.000112	0.00102	CbGpPWpGaD
Alosetron—CYP2E1—Metabolism—CYP4B1—urinary bladder cancer	0.000105	0.000961	CbGpPWpGaD
Alosetron—CYP3A4—Biological oxidations—GSTP1—urinary bladder cancer	0.000102	0.000933	CbGpPWpGaD
Alosetron—CYP3A4—Metapathway biotransformation—GSTP1—urinary bladder cancer	0.000101	0.00092	CbGpPWpGaD
Alosetron—CYP2E1—Metabolism—SLC19A1—urinary bladder cancer	9.93e-05	0.000908	CbGpPWpGaD
Alosetron—CYP2E1—Metabolism—PRSS3—urinary bladder cancer	9.68e-05	0.000885	CbGpPWpGaD
Alosetron—CYP2C9—Metabolism—GSTZ1—urinary bladder cancer	9.48e-05	0.000866	CbGpPWpGaD
Alosetron—CYP3A4—Biological oxidations—GSTM1—urinary bladder cancer	9.37e-05	0.000857	CbGpPWpGaD
Alosetron—CYP3A4—Metapathway biotransformation—GSTM1—urinary bladder cancer	9.25e-05	0.000845	CbGpPWpGaD
Alosetron—CYP2C9—Metabolism—GSTO2—urinary bladder cancer	8.98e-05	0.000821	CbGpPWpGaD
Alosetron—CYP2C9—Metabolism—NAT1—urinary bladder cancer	8.98e-05	0.000821	CbGpPWpGaD
Alosetron—CYP2C9—Metabolism of lipids and lipoproteins—HPGDS—urinary bladder cancer	8.84e-05	0.000808	CbGpPWpGaD
Alosetron—CYP2C9—Metabolism—UGT2B7—urinary bladder cancer	8.22e-05	0.000751	CbGpPWpGaD
Alosetron—CYP1A2—Metabolism—GSTZ1—urinary bladder cancer	8.1e-05	0.00074	CbGpPWpGaD
Alosetron—CYP2E1—Metabolism—TYMP—urinary bladder cancer	7.74e-05	0.000707	CbGpPWpGaD
Alosetron—CYP1A2—Metabolism—GSTO2—urinary bladder cancer	7.68e-05	0.000702	CbGpPWpGaD
Alosetron—CYP1A2—Metabolism—NAT1—urinary bladder cancer	7.68e-05	0.000702	CbGpPWpGaD
Alosetron—CYP1A2—Metabolism of lipids and lipoproteins—HPGDS—urinary bladder cancer	7.55e-05	0.00069	CbGpPWpGaD
Alosetron—CYP2C9—Metabolism—CYP4B1—urinary bladder cancer	7.4e-05	0.000676	CbGpPWpGaD
Alosetron—CYP1A2—Metabolism—UGT2B7—urinary bladder cancer	7.02e-05	0.000642	CbGpPWpGaD
Alosetron—CYP2E1—Metabolism—NAT2—urinary bladder cancer	7e-05	0.00064	CbGpPWpGaD
Alosetron—CYP2C9—Metabolism—SLC19A1—urinary bladder cancer	6.99e-05	0.000639	CbGpPWpGaD
Alosetron—CYP2C9—Metabolism—PRSS3—urinary bladder cancer	6.81e-05	0.000622	CbGpPWpGaD
Alosetron—CYP1A2—Metabolism—CYP4B1—urinary bladder cancer	6.32e-05	0.000578	CbGpPWpGaD
Alosetron—CYP3A4—Metabolism—GSTZ1—urinary bladder cancer	6.25e-05	0.000571	CbGpPWpGaD
Alosetron—CYP2E1—Metabolism—RRM2—urinary bladder cancer	6.04e-05	0.000552	CbGpPWpGaD
Alosetron—CYP1A2—Metabolism—SLC19A1—urinary bladder cancer	5.97e-05	0.000546	CbGpPWpGaD
Alosetron—CYP3A4—Metabolism—GSTO2—urinary bladder cancer	5.92e-05	0.000542	CbGpPWpGaD
Alosetron—CYP3A4—Metabolism—NAT1—urinary bladder cancer	5.92e-05	0.000542	CbGpPWpGaD
Alosetron—CYP1A2—Metabolism—PRSS3—urinary bladder cancer	5.82e-05	0.000532	CbGpPWpGaD
Alosetron—CYP2E1—Metabolism—ENO2—urinary bladder cancer	5.59e-05	0.000511	CbGpPWpGaD
Alosetron—CYP2E1—Metabolism—HPGDS—urinary bladder cancer	5.59e-05	0.000511	CbGpPWpGaD
Alosetron—CYP2C9—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	5.46e-05	0.000499	CbGpPWpGaD
Alosetron—CYP2C9—Metabolism—TYMP—urinary bladder cancer	5.44e-05	0.000498	CbGpPWpGaD
Alosetron—CYP2E1—Metabolism—GSTT1—urinary bladder cancer	5.42e-05	0.000496	CbGpPWpGaD
Alosetron—CYP3A4—Metabolism—UGT2B7—urinary bladder cancer	5.42e-05	0.000495	CbGpPWpGaD
Alosetron—CYP2C9—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	5.23e-05	0.000478	CbGpPWpGaD
Alosetron—CYP2C9—Metabolism—NAT2—urinary bladder cancer	4.92e-05	0.00045	CbGpPWpGaD
Alosetron—CYP3A4—Metabolism—CYP4B1—urinary bladder cancer	4.88e-05	0.000446	CbGpPWpGaD
Alosetron—CYP1A2—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	4.66e-05	0.000426	CbGpPWpGaD
Alosetron—CYP1A2—Metabolism—TYMP—urinary bladder cancer	4.65e-05	0.000425	CbGpPWpGaD
Alosetron—CYP3A4—Metabolism—SLC19A1—urinary bladder cancer	4.61e-05	0.000421	CbGpPWpGaD
Alosetron—CYP2E1—Metabolism—NQO1—urinary bladder cancer	4.51e-05	0.000412	CbGpPWpGaD
Alosetron—CYP3A4—Metabolism—PRSS3—urinary bladder cancer	4.49e-05	0.00041	CbGpPWpGaD
Alosetron—CYP1A2—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	4.47e-05	0.000408	CbGpPWpGaD
Alosetron—CYP2C9—Metabolism—RRM2—urinary bladder cancer	4.25e-05	0.000388	CbGpPWpGaD
Alosetron—CYP1A2—Metabolism—NAT2—urinary bladder cancer	4.21e-05	0.000385	CbGpPWpGaD
Alosetron—CYP2C9—Metabolism—ENO2—urinary bladder cancer	3.93e-05	0.00036	CbGpPWpGaD
Alosetron—CYP2C9—Metabolism—HPGDS—urinary bladder cancer	3.93e-05	0.00036	CbGpPWpGaD
Alosetron—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	3.91e-05	0.000358	CbGpPWpGaD
Alosetron—CYP2C9—Metabolism—GSTT1—urinary bladder cancer	3.82e-05	0.000349	CbGpPWpGaD
Alosetron—CYP2E1—Metabolism—GSTP1—urinary bladder cancer	3.76e-05	0.000344	CbGpPWpGaD
Alosetron—CYP2C9—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	3.76e-05	0.000344	CbGpPWpGaD
Alosetron—CYP1A2—Metabolism—RRM2—urinary bladder cancer	3.63e-05	0.000332	CbGpPWpGaD
Alosetron—CYP3A4—Metabolism—TYMP—urinary bladder cancer	3.59e-05	0.000328	CbGpPWpGaD
Alosetron—CYP2E1—Metabolism—TYMS—urinary bladder cancer	3.5e-05	0.00032	CbGpPWpGaD
Alosetron—CYP2E1—Metabolism—NCOR1—urinary bladder cancer	3.46e-05	0.000316	CbGpPWpGaD
Alosetron—CYP2E1—Metabolism—GSTM1—urinary bladder cancer	3.46e-05	0.000316	CbGpPWpGaD
Alosetron—CYP1A2—Metabolism—HPGDS—urinary bladder cancer	3.36e-05	0.000307	CbGpPWpGaD
Alosetron—CYP1A2—Metabolism—ENO2—urinary bladder cancer	3.36e-05	0.000307	CbGpPWpGaD
Alosetron—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	3.34e-05	0.000306	CbGpPWpGaD
Alosetron—CYP2E1—Metabolism—GPX1—urinary bladder cancer	3.31e-05	0.000303	CbGpPWpGaD
Alosetron—CYP1A2—Metabolism—GSTT1—urinary bladder cancer	3.26e-05	0.000298	CbGpPWpGaD
Alosetron—CYP2E1—Metabolism—ERCC2—urinary bladder cancer	3.25e-05	0.000297	CbGpPWpGaD
Alosetron—CYP3A4—Metabolism—NAT2—urinary bladder cancer	3.25e-05	0.000297	CbGpPWpGaD
Alosetron—CYP1A2—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	3.21e-05	0.000294	CbGpPWpGaD
Alosetron—CYP2C9—Metabolism—NQO1—urinary bladder cancer	3.17e-05	0.00029	CbGpPWpGaD
Alosetron—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	3.08e-05	0.000281	CbGpPWpGaD
Alosetron—CYP2E1—Metabolism—MTHFR—urinary bladder cancer	3.05e-05	0.000279	CbGpPWpGaD
Alosetron—CYP3A4—Metabolism—RRM2—urinary bladder cancer	2.8e-05	0.000256	CbGpPWpGaD
Alosetron—CYP1A2—Metabolism—NQO1—urinary bladder cancer	2.71e-05	0.000248	CbGpPWpGaD
Alosetron—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	2.68e-05	0.000245	CbGpPWpGaD
Alosetron—CYP2C9—Metabolism—GSTP1—urinary bladder cancer	2.65e-05	0.000242	CbGpPWpGaD
Alosetron—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	2.63e-05	0.00024	CbGpPWpGaD
Alosetron—CYP3A4—Metabolism—HPGDS—urinary bladder cancer	2.59e-05	0.000237	CbGpPWpGaD
Alosetron—CYP3A4—Metabolism—ENO2—urinary bladder cancer	2.59e-05	0.000237	CbGpPWpGaD
Alosetron—CYP2C9—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	2.56e-05	0.000234	CbGpPWpGaD
Alosetron—CYP3A4—Metabolism—GSTT1—urinary bladder cancer	2.52e-05	0.00023	CbGpPWpGaD
Alosetron—CYP2E1—Metabolism—PPARG—urinary bladder cancer	2.48e-05	0.000226	CbGpPWpGaD
Alosetron—CYP2C9—Metabolism—TYMS—urinary bladder cancer	2.46e-05	0.000225	CbGpPWpGaD
Alosetron—CYP2C9—Metabolism—NCOR1—urinary bladder cancer	2.43e-05	0.000222	CbGpPWpGaD
Alosetron—CYP2C9—Metabolism—GSTM1—urinary bladder cancer	2.43e-05	0.000222	CbGpPWpGaD
Alosetron—CYP2E1—Metabolism—CREBBP—urinary bladder cancer	2.38e-05	0.000217	CbGpPWpGaD
Alosetron—CYP2C9—Metabolism—GPX1—urinary bladder cancer	2.33e-05	0.000213	CbGpPWpGaD
Alosetron—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	2.29e-05	0.00021	CbGpPWpGaD
Alosetron—CYP2C9—Metabolism—ERCC2—urinary bladder cancer	2.29e-05	0.000209	CbGpPWpGaD
Alosetron—CYP1A2—Metabolism—GSTP1—urinary bladder cancer	2.26e-05	0.000207	CbGpPWpGaD
Alosetron—CYP1A2—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	2.19e-05	0.0002	CbGpPWpGaD
Alosetron—CYP2C9—Metabolism—MTHFR—urinary bladder cancer	2.15e-05	0.000196	CbGpPWpGaD
Alosetron—CYP1A2—Metabolism—TYMS—urinary bladder cancer	2.1e-05	0.000192	CbGpPWpGaD
Alosetron—CYP3A4—Metabolism—NQO1—urinary bladder cancer	2.09e-05	0.000191	CbGpPWpGaD
Alosetron—CYP1A2—Metabolism—GSTM1—urinary bladder cancer	2.08e-05	0.00019	CbGpPWpGaD
Alosetron—CYP1A2—Metabolism—NCOR1—urinary bladder cancer	2.08e-05	0.00019	CbGpPWpGaD
Alosetron—CYP1A2—Metabolism—GPX1—urinary bladder cancer	1.99e-05	0.000182	CbGpPWpGaD
Alosetron—CYP1A2—Metabolism—ERCC2—urinary bladder cancer	1.95e-05	0.000179	CbGpPWpGaD
Alosetron—CYP2E1—Metabolism—PTGS2—urinary bladder cancer	1.95e-05	0.000178	CbGpPWpGaD
Alosetron—CYP1A2—Metabolism—MTHFR—urinary bladder cancer	1.84e-05	0.000168	CbGpPWpGaD
Alosetron—CYP3A4—Metabolism—GSTP1—urinary bladder cancer	1.74e-05	0.000159	CbGpPWpGaD
Alosetron—CYP2C9—Metabolism—PPARG—urinary bladder cancer	1.74e-05	0.000159	CbGpPWpGaD
Alosetron—CYP2E1—Metabolism—PTEN—urinary bladder cancer	1.7e-05	0.000155	CbGpPWpGaD
Alosetron—CYP2C9—Metabolism—CREBBP—urinary bladder cancer	1.67e-05	0.000153	CbGpPWpGaD
Alosetron—CYP3A4—Metabolism—TYMS—urinary bladder cancer	1.62e-05	0.000148	CbGpPWpGaD
Alosetron—CYP2E1—Metabolism—EP300—urinary bladder cancer	1.62e-05	0.000148	CbGpPWpGaD
Alosetron—CYP3A4—Metabolism—GSTM1—urinary bladder cancer	1.6e-05	0.000147	CbGpPWpGaD
Alosetron—CYP3A4—Metabolism—NCOR1—urinary bladder cancer	1.6e-05	0.000147	CbGpPWpGaD
Alosetron—CYP3A4—Metabolism—GPX1—urinary bladder cancer	1.54e-05	0.00014	CbGpPWpGaD
Alosetron—CYP3A4—Metabolism—ERCC2—urinary bladder cancer	1.51e-05	0.000138	CbGpPWpGaD
Alosetron—CYP1A2—Metabolism—PPARG—urinary bladder cancer	1.49e-05	0.000136	CbGpPWpGaD
Alosetron—CYP1A2—Metabolism—CREBBP—urinary bladder cancer	1.43e-05	0.000131	CbGpPWpGaD
Alosetron—CYP3A4—Metabolism—MTHFR—urinary bladder cancer	1.42e-05	0.00013	CbGpPWpGaD
Alosetron—CYP2C9—Metabolism—PTGS2—urinary bladder cancer	1.37e-05	0.000125	CbGpPWpGaD
Alosetron—CYP2C9—Metabolism—PTEN—urinary bladder cancer	1.2e-05	0.000109	CbGpPWpGaD
Alosetron—CYP1A2—Metabolism—PTGS2—urinary bladder cancer	1.17e-05	0.000107	CbGpPWpGaD
Alosetron—CYP3A4—Metabolism—PPARG—urinary bladder cancer	1.15e-05	0.000105	CbGpPWpGaD
Alosetron—CYP2C9—Metabolism—EP300—urinary bladder cancer	1.14e-05	0.000104	CbGpPWpGaD
Alosetron—CYP3A4—Metabolism—CREBBP—urinary bladder cancer	1.1e-05	0.000101	CbGpPWpGaD
Alosetron—CYP1A2—Metabolism—PTEN—urinary bladder cancer	1.02e-05	9.34e-05	CbGpPWpGaD
Alosetron—CYP1A2—Metabolism—EP300—urinary bladder cancer	9.74e-06	8.9e-05	CbGpPWpGaD
Alosetron—CYP3A4—Metabolism—PTGS2—urinary bladder cancer	9.04e-06	8.26e-05	CbGpPWpGaD
Alosetron—CYP3A4—Metabolism—PTEN—urinary bladder cancer	7.88e-06	7.21e-05	CbGpPWpGaD
Alosetron—CYP3A4—Metabolism—EP300—urinary bladder cancer	7.52e-06	6.87e-05	CbGpPWpGaD
